Suppr超能文献

Kimura 病的诊断挑战和更新的治疗策略:一例成功接受度普利尤单抗治疗的病例报告及综述。

Diagnostic challenges and updated therapeutic strategies of Kimura's disease: A case report successfully treated by dupilumab and review.

机构信息

Department of Hematology, Lyon Sud Hospital, Hospices Civils de Lyon, Pierre-Bénite, France.

Claude Bernard Lyon 1 University, Lyon, France.

出版信息

Medicine (Baltimore). 2023 Nov 24;102(47):e34191. doi: 10.1097/MD.0000000000034191.

Abstract

RATIONALE

Kimura's disease (KD) is a rare and chronic eosinophilic related-disease, characterized by subcutaneous tissue masses, regional enlarged lymph nodes, hypereosinophilia and elevated serum IgE. KD usually affects young adults in the Asian population. In Western countries, the clinical and biological presentation of KD is often unknown, delaying the diagnosis. Therapeutic management is not standardized and despite recent advances, remission from KD can be difficult to achieve, especially in relapse situations.

PATIENT CONCERNS

We report the case of an non-Asian man with KD, initially misdiagnosed as lymphoma. We focus on his long-lasting clinical course with 20 years of recurrence despite several therapeutic lines.

DIAGNOSES AND INTERVENTIONS

We have emphasized the key points of the KD diagnostic challenge. We chose to focus on hemopathies as diagnostic traps to illustrate several overlapping features that blur frontiers with KD. With regard to treatments, lessons can be learned from the use of the therapeutic backbone, which relies on excision surgery, radiotherapy and corticosteroids.

OUTCOMES

Advancements in KD pathogenesis have highlighted the pivotal role of Th2 lymphocytes driving eosinophil activation. Directly inspired by eosinophilic and allergic field practices, targeted therapies, such as dupilumab, provide hope for potential curative options.

LESSONS

Finally, we propose a therapeutic plan to treat newly diagnosed KD and discuss options for relapsing entities.

摘要

背景

Kimura 病(KD)是一种罕见的慢性嗜酸性粒细胞相关疾病,其特征为皮下组织肿块、区域性淋巴结肿大、嗜酸性粒细胞增多和血清 IgE 升高。KD 通常影响亚洲人群中的年轻成年人。在西方国家,KD 的临床和生物学表现常常不为人知,导致诊断延误。治疗管理尚未标准化,尽管最近有所进展,但 KD 缓解可能难以实现,尤其是在复发情况下。

病例报告

我们报告了一例非亚洲人 KD 患者,最初误诊为淋巴瘤。我们重点介绍了他长达 20 年的反复发作的长期临床病程,尽管进行了多种治疗线。

诊断挑战

我们强调了 KD 诊断挑战的关键点。我们选择关注血液系统疾病作为诊断陷阱,以说明几个重叠的特征,这些特征模糊了与 KD 的界限。在治疗方面,可以从以切除手术、放疗和皮质类固醇为基础的治疗方法中吸取经验教训。

发病机制的进展强调了 Th2 淋巴细胞驱动嗜酸性粒细胞活化的关键作用。受嗜酸性粒细胞和过敏领域实践的启发,靶向治疗,如 dupilumab,为潜在的治愈选择提供了希望。

最后,我们提出了一个治疗新诊断 KD 的方案,并讨论了复发实体的治疗选择。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2268/10681606/2e37ebb48025/medi-102-e34191-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验